The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...